An FDA advisory committee recommended against approving paroxetine for menopausal vasomotor symptoms. But recognizing the lack of hormone-free products for this indication, and after reviewing the drug's efficacy and safety, the FDA decided it can benefit some women.
No takes yet. Share an insight, caveat, or question.
Orleans et al. (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: